Assertio Holdings heads into its Q1 2026 earnings print — expected around May 5-8 — with short interest jumping sharply over the past week, options tilting heavily toward calls, and a pending acquisition deal still unresolved.
The most eye-catching move this week is in short interest. Shares short climbed roughly 18.5% over the past seven days, rising to around 5.2% of free float. That's a notable acceleration from the steadier base of 3.5-4% that prevailed through most of March and early April. The jump corresponds closely with news flow around Assertio's tender offer for Garda Therapeutics, which the company extended again on April 29 — the third update in as many weeks. Deal uncertainty appears to be driving at least some of the fresh short positioning.
Borrow conditions are loose rather than tight. Availability runs at a very high 1,827% of short interest — meaning shares available to borrow vastly outnumber those already lent out. Cost to borrow has stayed near 0.48% annually, down sharply from the 3.7% spike seen on April 8 during peak broad-market stress. There's no squeeze pressure in the lending market right now. Short sellers face minimal friction building or holding positions, and the ORTEX short score of 40.2 is mid-range — elevated from 36 a week ago, but not yet signalling the kind of extreme pressure that precedes forced covering.
Options tell the opposite story. The put/call ratio collapsed to just 0.006 on April 29 — one of the lowest readings of the past year and well below the 20-day average of 0.10. That's an almost entirely call-dominated flow. Taken at face value, it suggests traders are positioning for upside rather than hedging against downside. The divergence between rising short interest and overwhelmingly bullish options flow is the central tension heading into earnings.
On valuation, the picture is complicated by Assertio's transition. The EV/EBITDA multiple is running near 4x — inexpensive in absolute terms — but the PE has expanded sharply, up more than 35 points over the past 30 days to nearly 40x. Q4 2025 results released in March showed revenue of $13.5 million, down from $32.2 million a year earlier. Net loss widened to $11.9 million. The Nantahala Capital Management stake of 10.7% remains the dominant institutional position, with modest additions from Vanguard and Huntleigh Advisors as of the March quarter-end. Insider activity in February was limited to routine award-and-sell transactions at prices around $11.84 — well below current levels — and carries a low significance score.
The last earnings event in March produced a strong market reaction: the stock rose 8.3% on the day and 21.3% over the following five sessions. Whether Assertio's Q1 report — due just days away — can generate a comparable response depends on whether the Garda deal provides any clarity, and how revenue tracks given the company's ongoing product portfolio restructuring.
See the live data behind this article on ORTEX.
Open ASRT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
